β₂ adrenergic agonist suppresses eosinophil-induced epithelial-to-mesenchymal transition of bronchial epithelial cells

Keigo Kainuma¹,², Tetsu Kobayashi³, Corina N. D’Alessandro-Gabazza², Masaaki Toda², Taro Yasuma², Kota Nishihama², Hajime Fujimoto⁴, Yu Kuwabara¹,², Koa Hosoki¹,², Mizuho Nagao¹, Takao Fujisawa¹ and Esteban C. Gabazza²*

Abstract

Background: Epithelial-mesenchymal transition is currently recognized as an important mechanism for the increased number of myofibroblasts in cancer and fibrotic diseases. We have already reported that epithelial-mesenchymal transition is involved in airway remodeling induced by eosinophils. Procaterol is a selective and full β₂ adrenergic agonist that is used as a rescue of asthmatic attack inhaler form and orally as a controller. In this study, we evaluated whether procaterol can suppress epithelial-mesenchymal transition of airway epithelial cells induced by eosinophils.

Methods: Epithelial-mesenchymal transition was assessed using a co-culture system of human bronchial epithelial cells and primary human eosinophils or an eosinophilic leukemia cell line.

Results: Procaterol significantly inhibited co-culture associated morphological changes of bronchial epithelial cells, decreased the expression of vimentin, and increased the expression of E-cadherin compared to control. Butoxamine, a specific β₂-adrenergic antagonist, significantly blocked changes induced by procaterol. In addition, procaterol inhibited the expression of adhesion molecules induced during the interaction between eosinophils and bronchial epithelial cells, suggesting the involvement of adhesion molecules in the process of epithelial-mesenchymal transition. Forskolin, a cyclic adenosine monophosphate-promoting agent, exhibits similar inhibitory activity of procaterol.

Conclusions: Overall, these observations support the beneficial effect of procaterol on airway remodeling frequently associated with chronic obstructive pulmonary diseases.

Keywords: Asthma, Eosinophils, Epithelial cells, Integrins

Background

Obstructive pulmonary diseases such as bronchial asthma and chronic obstructive pulmonary disease are chronic inflammation of the airways that are frequently associated with lung structural changes, termed airway remodeling [1, 2]. The pathogenesis of airway remodeling has not been fully elucidated. It may be a consequence of airway inflammation [3, 4]. β₂ adrenergic agonists are not only the first line drug for relief of acute asthma symptoms but a long-term controller in combination with inhaled corticosteroids. Procaterol is a selective and full β₂ adrenergic agonist that is used as a rescue of asthmatic attack in inhaler form and orally as a controller [5]. Studies in vitro have shown that β₂ selective-agonists exert anti-inflammatory activity. β₂ selective-agonists increase cyclic AMP levels, which inhibit mast cell and eosinophil degranulation, apoptosis and cytokine production [6–9]. Procaterol can also reduce the expression of adhesion molecules [6, 10]. A previous study has shown that systemic administration of tulobuterol, a β₂-selective agonist,
decreases eosinophil adhesion to endothelial cells resulting in reduction of eosinophil inflammation [11]. β2 adrenergic agonists are also very effective bronchodilators in COPD and they are part of the therapeutic strategy for the management of COPD patients [12, 13]. Short acting or long acting β2 agonists are administered in clinical practice through inhaler devices whose delivery efficiency has substantially improved by the use of computational models [13-17].

Epithelial to mesenchymal transition (EMT) leads to increased number of myofibroblasts in cancer and fibrotic diseases [18]. Eosinophils can cause airway remodeling by promoting EMT [19]. Recently, we and others have reported that direct contact of eosinophils with bronchial epithelial cells increases the expression of TGF-β1 leading to induction of EMT [20]. In the present study, we hypothesized that procaterol can suppress EMT of airway epithelial cells induced by eosinophils.

Methods

Reagent

L-glutamine, penicillin/streptomycin, donkey anti-mouse IgG-Alexa Fluor 488, Chicken anti-rabbit IgG-Alexa Fluor 594, Laemmli sample buffer and Trizol Reagent were purchased from Invitrogen (Carlsbad, CA). Dulbecco’s modified Eagle’s medium (DMEM), RPMI-1640 and bovine serum albumin (BSA) were from Sigma (St Louis, MO), and fetal bovine serum (FBS) from Thermo scientific. Rabbit anti α-SMA, anti-CD16 and anti-CD14 bound micromagnetic beads were purchased from Miltenyi Biotec (Auburn, CA), mouse anti-human E-cadherin antibody from BD Biosciences (Mississauga, ON, Canada), and anti-TGF-β1 monoclonal antibody (mAb) (1D11) from R&D Systems (Minneapolis, MN). Sepasol-RNA I super G (Nacalai tesque), anti-mouse antibodies against CD11b (integrin αM), CD49d (integrin α4), CD29 (integrin β1), CD18 (integrin β2), CD54 (ICAM-1), and CD106 (VCAM-1) were from BioLegend.

Cell lines

BEAS-2B, an adenovirus 12-SV40 virus hybrid (Ad12SV40) transformed human epithelial cells, was obtained from the Riken Cell Bank (Tsukuba, Japan), and cultured in DMEM supplemented with 10% (v/v) heat-inactivated FBS, 0.03% (w/v) L-glutamine, 100 IU/ml penicillin and 100 μg/ml streptomycin. EoL-1 cells were obtained from the Riken Cell Bank, maintained in suspension culture at 37 °C and 5%CO2 in humidified atmosphere using RPMI-1640 medium supplemented with 10%(v/v) heat-inactivated FBS, 0.03%(w/v) L-glutamine, 100 IU/ml penicillin and 100 μg/ml streptomycin. For differentiation, EoL-1 cells were diluted to 5 × 105 cells/ml and 0.5 mM sodium n-butylate (BA) was added. EoL-1 cells were incubated with 0.5 mM BA for 5 days.

Preparation of human eosinophils

Eosinophils from healthy human volunteers (age 30 to 45 years old with no present history of any disease) were purified by negative selection using anti-CD16 and anti-CD14 bound micromagnetic beads as previously described [19]. The purity of eosinophils was more than 97% as measured by the Randoph’s phloxine-methylene blue stain [21].

Co-culture experiment and morphological analysis

BEAS-2B cells were cultured in 6- or 12-well plates until 60–70% cell confluence, then serum-starved for 24 h. Eosinophils were pre-treated with procaterol (provided by Otsuka Pharmacy) at 10−9 M for 1 h. Human eosinophils (1 × 106 cells for 12-well plate, 2 × 106 cells for 6-well plate) were added to the culture RPMI medium and incubated for further 24 h. After co-culture, human eosinophils were removed from adherent BEAS-2B cells by gentle pipetting. BEAS-2B cells were stained by Diff-Quick technique and photographed for analyzing morphological changes. For immunofluorescence, cells were fixed with 4% paraformaldehyde for 10 min at room temperature and stained with mouse anti-E-cadherin mAb and anti-α-SMA Ab (rabbit polyclonal) followed by the secondary antibodies (donkey anti-mouse IgG conjugated with AF488 and chicken anti-rabbit IgG conjugated with AF594). Deparaffinized tissue sections were subjected to hydrated autoclaving for antigen retrieval. After washing with Tris-buffered saline, slides were exposed to mouse anti–human E-cadherin antibody (1:200) overnight at 4 °C and subsequently incubated with donkey anti-mouse IgG-Alexa Fluor 488 (1:200) for 4 h at room temperature after washing. Staining of α-SMA was done using rabbit anti–human α-SMA antibody (1:200) and then chicken anti-rabbit IgG-Alexa Fluor 594 (1:200). After washing, the sections were counterstained with 4,6-diamidino-2-phenylindole (DAPI) and mounted using a fluorescence mounting medium.

In separate experiments, human eosinophils (2 × 105 cells) were prepared and treated with 10−7 M procaterol or 10−5 M forskolin (Nacalai Tesque, Kyoto, Japan) for 30 min at 37 °C. A group of eosinophils was then co-cultured with serum-starved semi-confluent BEAS-2B cells (2.5 × 105 cells/well, 12-well plate) for 24 h and the cell surface expression of integrins on eosinophils was evaluated by flow cytometry. Control eosinophils were cultured alone for 24 h. Another group of eosinophils was co-cultured with BEAS-2B cells for 48 h and the cell supernatants and adherent cells (BEAS-2B cells) were collected for analysis of cytokine expression by RT-PCR and immunoassays.

Reverse transcriptase polymerase chain reaction (RT-PCR)

After co-culture of BEAS-2B cells and eosinophils for 24 h, eosinophils were removed as described above. Total RNA was extracted from BEAS-2B cells by the
guanidine isothiocyanate procedure using Trizol Reagent. RNA was reverse-transcribed using oligo-dT primers and then the DNA was amplified by PCR. The sequences of the primers are as follows: for human vimentin, forward 5′-GAGAACTTTGCCGTTGAAGC-3′ and reverse 5′-GCTTCCTGTAGGTGGTGGAATC-3′; for human E-cadherin forward: 5′-GTATCTTCCCCGCCCTGCCAATCC-3′ and reverse 5′-CCTGGCCGATAGAATGAGACCCTG-3′; for human GAPDH, forward 5′-GTGAAGGTCGGACTCAACGGA-3′ and reverse 5′-GGTGAAAGACGCCAGTGACTG-3′. PCR was carried for 35 cycles (E-cadherin), 27 cycles (Vimentin), 25 cycles (GAPDH), denaturation at 94 °C for 30s, annealing at 65 °C for E-cadherin and GAPDH, and 59 °C for vimentin for 30s, and elongation at 72 °C for 1 min; at the end of these cycles, a further extension was carried out at 72 °C for 5 min. The PCR products were separated on a 2% agarose gel containing 0.01% ethidium bromide. The RNA concentration and purity were determined by UV absorption at 260:280 using an UltraSpec 1100 pro UV/Vis spectrophotometer (Amersham Biosciences, NJ). The amount of mRNA was normalized against the GAPDH mRNA.

**Immunohistochemistry**

The immunoassay kit for measuring transforming growth factor (TGF)-β1 (R&D, McKinley Place, MN) and granulocyte-macrophage colony-stimulating factor (GM-CSF) were purchased from BD Biosciences Pharmin-gen (San Jose, CA); and each parameter was measured following the manufacturer’s instructions.

![Fig. 1](image-url) EMT induced by EoL-1 is inhibited by procaterol. **a** Control and BEAS-2B cells co-cultured with EoL-1 in the presence or absence of procaterol (original magnifications, ×400). **b** Gene expression of E-cadherin and vimentin in BEAS-2B cells co-cultured with EoL-1 in the presence (10⁻⁹ M ~ 10⁻⁶ M) or absence of procaterol as evaluated by RT-PCR. **c** Granulocyte-macrophage colony-stimulating factor (GM-CSF) and transforming growth factor (TGF-β1) levels in the supernatant after co-culture in the presence (10⁻⁹ M ~ 10⁻⁶ M) or absence of procaterol. Bars indicate mean ± SEM. Scale bars indicate 100 μm. The data are the representative of a single experiment performed in triplicates. Two independent experiments were performed. *p < 0.0001 vs procaterol 0 group; **p < 0.001 and ¶p < 0.05 vs EoL-1(+)/procaterol (−) group. Statistics by analysis of variance with Dunnett’s test.
Statistical analysis

All data were expressed as the mean ± standard error of the mean (S.E.M.). The statistical difference between two variables was calculated by the Mann–Whitney U test, and that between three or more variables by one-way analysis of variance with Dunnett’s test. We used the software package GraphPad Prism 6 (GraphPad Software, San Diego, CA) for all statistical analyses. $P < 0.05$ was considered as statistically significant.

Results

Procaterol inhibits EMT induced by human EoL-1 cells

BEAS-2B cells were co-cultured with EoL-1 in the presence or absence of procaterol. BEAS-2B cells cultured in medium alone conserved the typical epithelial cobblestone pattern, but BEAS-2B cells co-cultured with EoL-1 presented fibroblast-like morphology consistent with EMT (Fig. 1a). Procaterol inhibited these morphological changes. RT-PCR analysis showed that procaterol significantly inhibited the decrease in the expression of the epithelial marker E-cadherin and the increase in the expression of the mesenchymal marker vimentin in BEAS-2B cells co-cultured with EoL-1 in a concentration-dependent manner (Fig. 1b). Pre-treatment with procaterol significantly and dose-dependently inhibited the increase of TGF-$\beta$1 and GM-CSF in the culture supernatant sampled during co-culture of BEAS-2B cells with human EoL-1 cells (Fig. 1c).

Subsequent investigations were performed using procaterol at concentration of $10^{-7}$ M because the optimal effective concentration of procaterol in human is between $10^{-8}$ M ~ $10^{-7}$ M.

Procaterol inhibits EMT induced by primary human eosinophils

BEAS-2B cells were co-cultured with primary human eosinophils in the presence or absence of procaterol. BEAS-2B cells co-cultured with human eosinophils exhibited fibroblast-like morphology consistent with EMT, but this was inhibited when human eosinophils were pre-treated with procaterol. BEAS-2B cells co-cultured with human eosinophils showed spindle forms; culture in the presence of procaterol inhibited these morphological changes (Fig. 2a). RT-PCR analysis showed that procaterol significantly inhibited the decrease in the expression of E-cadherin and the increased expression of vimentin in BEAS-2B cells co-cultured with human eosinophils (Fig. 2b). Pre-treatment with procaterol significantly inhibited the increase of TGF-$\beta$1 and GM-CSF in the supernatant obtained during co-culture of BEAS-2B cells with human eosinophils (Fig. 2c).
Immunofluorescence staining of E-cadherin (green) and α-SMA (red) in BEAS-2B cell was also performed. Procaterol significantly inhibited the decrease in the expression of E-cadherin and the increase in the expression of α-SMA in BEAS-2B cells co-cultured with human eosinophils (Fig. 2d, e).

**Butoxamine, a specific β2-adrenergic antagonist, inhibits the effect of procaterol**

BEAS-2B cells pretreated with butoxamine before adding procaterol, and co-cultured with human eosinophils showed fibroblast-like morphology (Fig. 3a). RT-PCR analysis showed that butoxamine significantly inhibited the expression of E-cadherin and vimentin in BEAS-2B cells co-cultured with human eosinophils (Fig. 3b). Pretreatment with butoxamine significantly blocked changes induced by procaterol on secretion of TGF-β1 and GM-CSF in the cell supernatant during co-culture of BEAS-2B cells with human eosinophils (Fig. 3c).

**Procaterol inhibits the expression of adhesion molecules**

We have already reported the need of eosinophil contact to induce EMT of bronchial epithelial cells, thus we analyzed the expression of adhesion molecules on eosinophils by flow cytometry. The expression of the adhesion molecules ICAM-1 and VCAM-1 on BEAS-2B cells pretreated with butoxamine before adding procaterol showed a significant decrease compared to the control (Fig. 3a).

![Fig. 3 A specific β2 adrenergic receptor inhibitor blocks the effect of procaterol. a Control and BEAS-2B cells co-cultured with human eosinophils in the presence or absence of procaterol and butoxamine (original magnifications, x400). b Gene expression of E-cadherin and vimentin as evaluated by RT-PCR. c Granulocyte-macrophage colony-stimulating factor (GM-CSF) and transforming growth factor (TGF-β1) levels in the supernatant. Bars indicate mean ± SEM. Scale bars indicate 100 μm. The data are the representative of a single experiment performed in triplicates. Three independent experiments were performed. *p < 0.005 vs butoxamine (-)/procaterol (-) group; **p < 0.005 vs butoxamine (-)/procaterol (+) group. Statistics by analysis of variance with Dunnett’s test.](image-url)
cells co-cultured with EoL-1 cells were enhanced in the absence of procaterol but it was inhibited when EoL-1 cells were pretreated with procaterol before co-culturing with BEAS-2B cells (Fig. 4a, b).

The expressions of α4(CD49d), β1(CD29), αM(CD11b) and β2(CD18) integrin subunits were also evaluated during co-culture in the presence or absence of procaterol. The expression of CD49d, CD29, CD11b and CD18 were strongly enhanced when BEAS-2B cells were co-cultured with eosinophils pretreated without procaterol, but they were significantly inhibited when eosinophils were pretreated with procaterol (Fig. 5a, b).

Fig. 4 Procaterol inhibits the expression of adhesion molecules from BEAS-2B cells co-cultured with EoL-1 cells. a The expression of ICAM-1 and VCAM-1 on BEAS-2B cells co-cultured with EoL-1 cells in the presence or absence of procaterol as analyzed by flow-cytometry. b Quantification by MFI. Bars indicate mean ± SEM. The data are the representative of a single experiment performed in triplicates. Two independent experiments were performed.*p < 0.001 vs EoL-1 (−)/procaterol (−) group; **p < 0.05 vs EoL-1 (+)/procaterol (−) group. Statistics by analysis of variance with Dunnett’s test.
Suppression of EMT by antibodies against integrin and/or anti-adhesion molecules

The role of adhesion molecules in EMT during co-culture was evaluated. The characteristic morphological changes of EMT in BEAS-2B cells co-cultured with eosinophils were abolished in the presence of anti-integrin antibodies (anti-CD18 Ab and/or anti-CD29 Ab) (Fig. 6a). Anti-integrin antibodies also significantly inhibited the decreased expression of E-cadherin, and the increased expression of vimentin (Fig. 6b).

EMT of BEAS-2B cells was inhibited in the presence of anti-ICAM-1 antibody (anti-CD54 Ab) (Fig. 7a). Anti-ICAM-1 antibody significantly inhibited the inhibitory effect of procaterol on the expression of TGF-β1 and GM-CSF during co-culture of BEAS-2B cells with human eosinophils (Fig. 7b). The decreased expression of
E-cadherin, and the increased expression of vimentin (Fig. 7c) were also significantly inhibited by anti-ICAM-1 antibody (Fig. 7c).

Forskolin exerts similar effects of procaterol
To demonstrate that increased intracellular levels of cyclic adenosine monophosphate (cAMP) is critical for the inhibitory activity of procaterol, we evaluated whether similar effects can be observed with forskolin, a well-recognized activator of adenylyl cyclase. As expected the surface expression of integrins (CD11b, CD18, CD49d, CD29) on eosinophils co-cultured with BEAS-2B cells was significantly inhibited by forskolin compared to control cells (Fig. 8a, b). In addition, the mRNA expression of E-cadherin was significantly increased while that of vimentin was significantly decreased in BEAS-2B cells co-cultured with eosinophils treated with forskolin compared to control cells (Fig. 8c). The concentrations of TGF-β1 and GM-CSF were also significantly suppressed in the co-culture supernatant in the presence of forskolin compared to control (Fig. 8d). EMT was also inhibited in epithelial cells co-cultured in the presence of eosinophils pre-treated with procaterol or forskolin (Fig. 8e).

Discussion
The results of this study provide the first evidence that procaterol, a selective and full β2-agonist, suppresses EMT of bronchial epithelial cells induced by eosinophils.

Adhesion molecules and airway remodeling
EMT of airway epithelial cells plays an important role in airway remodeling associated chronic bronchial asthma [22–26]. Mesenchymal cells during EMT migrate to the subepithelial connective tissue where they produce extracellular matrix proteins and contribute to airway wall fibrosis [27]. We previously reported that direct contact of eosinophils with the BEAS-2B cells increases the expression of TGF-β1 and induces EMT [20]. Hansel et al. reported that adhesion molecules on eosinophils play crucial roles in bronchial asthma [28]. We found that neither increase in the level of supernatant TGF-β1 nor induction of EMT occurs when the cells are cultured
using a trans-well system suggesting the need of cell contact. Adhesion molecules play a critical role in cell-to-cell interaction [20]. Here, we showed that co-culture of epithelial cells and eosinophils up-regulates the expression of integrins on eosinophils and ICAM-1 and VCAM-1 on epithelial cells, and that inhibition of integrin-mediated cell-contact inhibits EMT of epithelial cells. Integrin-mediated signaling in eosinophils appears to induce the production of TGF-β1 leading to EMT of epithelial cells. In the present study, we found that procaterol inhibits the expression of adhesion molecules from eosinophils and that EMT is suppressed in the presence of anti-adhesion molecule antibodies during co-culture of bronchial epithelial cells with primary eosinophils. Inhibition of the expression of adhesion molecules appears to be associated with increased intracellular cyclic AMP activation [6]. In support of this, we found that the effect of forskolin, a cAMP-promoting agent, is similar to that of procaterol. A previous study has shown that suppression of RhoA activation by increased intracellular levels of cAMP inhibits integrin-dependent adhesion of leukocytes [29]. Therefore, it is conceivable that elevation of intracellular levels of cAMP is the mechanism by which procaterol decreases activation of eosinophils leading to downregulated expression of integrin molecules and TGF-β1 in eosinophils making them less capable of inducing EMT. All together, these observations suggest that procaterol suppresses eosinophil-induced EMT by blocking the expression of adhesion molecules on eosinophils. It is worth noting that, in addition to eosinophils, other cells including macrophages and neutrophils are also capable of inducing EMT [30, 31].

**Bronchoconstriction and TGF-β1 expression**

β2 adrenergic agonists are the first line drug for relief of acute asthma symptoms and a long-term controller in combination with inhaled corticosteroids [2]. They are the key bronchodilators used in the reversal of acute bronchospasm of bronchial asthma and for the treatment of COPD [1, 2]. These agonists may also have important

---

Fig. 8 Forskolin and procaterol have similar effects. a, b Human eosinophils were pre-treated with procaterol or forskolin for 30 min and then co-cultured with serum-starved BEAS-2B for 24 h before analyzing integrin expression by flow cytometry. c BEAS-2B cells were collected to evaluate the mRNA expression of E-cadherin and vimentin. d Co-culture supernatants were collected to evaluate the levels of transforming growth factor (TGF-β1) and granulocyte-macrophage colony-stimulating factor (GM-CSF). e EMT of BEAS-2B cells were evaluated in each treatment group. Bars indicate mean ± SEM. Scale bars indicate 100 μm. The data are the representative of a single experiment performed in triplicates. *p < 0.05 vs control groups; **p < 0.05 vs eosinophils co-cultured with BEAS-2B in the absence of both procaterol and forskolin. Statistics by analysis of variance with Dunnett’s test.
anti-inflammatory effects on eosinophils in airway chronic diseases [7]. Grainge et al. showed that bronchoconstriction without additional inflammation induced airway remodeling in patients with asthma [32]. They found that bronchoconstriction induced by either allergen or methacholine increases TGF-β1 production from the airway epithelium. This previous study also provided evidence that repeated bronchoconstriction increases the thickness of the sub-epithelial collagen layer, which is an early indicator of airway collagen deposition and epithelial mesenchymal signaling [32]. In the present study, TGF-β1 secretion was suppressed by procaterol. Thus prevention of airway contraction by using β2 agonists may lead to amelioration of airway remodeling.

Study limitations
The purity of eosinophils was not 100%, and thus EMT could have been caused by hematopoietic cells rather than eosinophils. However, in a previous study we demonstrated that eosinophils isolated using the same method, but not contaminating cells, promote EMT in the model used here [19]. The fact that EMT induced by a eosinophil cell line (Eol-1) was inhibited by procaterol also supports the role of human eosinophils in our present model of EMT. The lack of an in vivo study is another limitation; but we already reported that eosinophils play an important role in airway remodeling in vivo and that procaterol at a clinical dose reduces eosinophil inflammation [19]. Therefore, it is likely that suppression of eosinophils-induced EMT by procaterol is a relevant mechanism even in vivo.

Conclusions
In summary, this study showed that procaterol, β2 adrenergic agonists, suppresses eosinophils-induced EMT of airway epithelial cells, and this finding may explain the mechanism by which β2 adrenergic agonists ameliorate airway remodeling in chronic obstructive pulmonary diseases including bronchial asthma.

Abbreviations
EMT: Epithelial-to-mesenchymal transition; GM-CSF: Granulocyte-macrophage colony-stimulating factor; ICAM-1: Intercellular Adhesion Molecule 1; mAb: Monoclonal antibody; TGF-β1: Transforming growth factor; VCAM-1: Vascular cell adhesion molecule 1

Acknowledgement
We are grateful to Miyuki Ieda for her assistance in the preparation of the manuscript.

Funding
The research was financially supported in part by a Grant (No 17 K08442) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (C.D.G., E.C.G.).

Availability of data and materials
All raw data and materials are available Mie University Graduate School of Medicine.

Authors’ contributions
Conception and design: TF, ECG. Cell culture: MT, KK, CND-G, TY. Cellular analysis: MT, HF, YK, MN. Data analysis and interpretation: KN, TK, ECG, KH. Preparation of the manuscript draft: KK, ECG, TF. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
All authors agreed with the publication of the results of this study.

Ethics approval and consent to participate
Written informed consent was obtained from all healthy volunteers before blood sampling. The protocol of this study was approved by the Institutional Ethic Board for Clinical Investigation.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Allergy Center, Mie National Hospital, 357 Osato-kubota, Tsu, Mie 514-0125, Japan. 2Department of Immunology, Mie University Graduate School of Medicine, Edobashi 2-174, Tsu, Mie 514-8507, Japan. 3Department of Pulmonary and Critical Care Medicine, Mie University Graduate School of Medicine, Edobashi 2-174, Tsu, Mie 514-8507, Japan.

Received: 26 February 2017 Accepted: 25 April 2017
Published online: 02 May 2017

References
1. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343:269–80.
2. Busse WW, Lemanske Jr RF. Asthma. N Engl J Med. 2001;344:350–62.
3. William W, Busse Jr Jr FL. Asthma. N Engl J Med. 2001;344:351–62.
4. Elias JA, Lee CG, Zheng T, Ma B, Homer RJ, Zhu Z. New insights into the pathogenesis of asthma. J Clin Invest. 2003;111:291–7.
5. Eidon MA, Blake DS, Coon MJ, Nordblom GD, Sedman AJ, Colburn WA. Clinical pharmacokinetics of procaterol: dose proportionality after administration of single oral doses. Biopharm Drug Dispos. 1992;13:663–9.
6. Momose T, Okubo Y, Horie S, Suzuki J, Isobe M, Sekiguchi M. Effects of intracellular cyclic AMP modulators on human eosinophil survival, degranulation and CD11b expression. Int Arch Allergy Immunol. 1998;117:138–45.
7. Hanania NA, Moore RH. Anti-inflammatory activities of beta2-agonists. Curr Drug Targets Inflamm Allergy. 2004;3:271–7.
8. Butchers PR, Vardey CJ, Johnson M. Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung. Br J Pharmacol. 1991;104:672–6.
9. Ezeamuzie CI, al-Hage M. Differential effects of salbutamol and salmeterol on human eosinophil responses. J Pharmacol Exp Ther. 1998;284:26–31.
10. Koyama S, Sato E, Masubuchi T, Takamizawa A, Kubo K, Nagai S, Isumi T. Procaterol inhibits IL-1beta- and TNF-alpha-mediated epithelial cell eosinophil chemotactic activity. Eur Respir J. 1999;14:767–75.
11. Yamaguchi T, Nagata M, Miyazawa H, Kikuchi I, Kikuchi S, Kikuchi S, Hagiwara K, Kanazawa M. Tulobuterol, a β2 agonist, attenuates eosinophil adhesion to endothelial cells. Allergol Int. 2005;54:283–8.
12. Ohbayashi H, Adachi M. Pretreatment with inhaled procaterol improves symptoms of dyspnea and quality of life in patients with severe COPD. Int J Gen Med. 2012;5:517–24.
13. Taslkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14:449.
14. Ninane V, Vandevoorde J, Cataldo D, Derom E, Liistro G, Munghen E, Peche R, Schlesser M, Verleden G, Vincen W. New developments in inhaler devices within pharmaceutical companies: a systematic review of the impact on clinical outcomes and patient preferences. Respir Med. 2015;109:1430–8.
15. Kannan R, Przekwas AJ, Singh N, Delvadia R, Tian G, Walenga R. Pharmacological aerosols deposition patterns from a dry powder inhaler: Euler Lagrangian prediction and validation. Med Eng Phys. 2017;42:35–47.

16. Kannan R, Guo P, Przekwas A. Particle transport in the human respiratory tract: formulation of a nodal inverse distance weighted Euler-Lagrange transport and implementation of the Wind-Kessel algorithm for an oral delivery. Int J Numer Methods Biomed Eng. 2016;32:e02746.

17. Kannan R, Chen ZJ, Singh N, Przekwas A, Delvadia R, Tian G, Walenga R. A quasi-3D wire approach to model pulmonary airflow in human airways. Int J Numer Methods Biomed Eng. 2016;33:e02838.

18. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172:973–81.

19. Hosoki K, Kainuma K, Toda M, Harada E, Chelakkot-Govindalayathila AL, Rozen Z, Nagao M, D’Alessandro-Gabazza CN, Fujisawa T, Gabazza EC. Montelukast suppresses epithelial to mesenchymal transition of bronchial epithelial cells induced by eosinophils. Biochem Biophys Res Commun. 2014;449:351–6.

20. Yasukawa A, Hosoki K, Toda M, Miyake Y, Matsushima Y, Matsumoto T, Boveda-Ruiz D, Gil-Bernabe P, Nagao M, Sugimoto M, Hiraguchi Y, Tokuda R, Naito M, Takagi T, D’Alessandro-Gabazza CN, Suga S, Kobayashi T, Fujiwara T, Taguchi Q, Gabazza EC. Eosinophils promote epithelial to mesenchymal transition of bronchial epithelial cells. PLoS ONE. 2013;8:e64281.

21. Randolph TG. Blood studies in allergy; variations in eosinophils following test feeding of foods. J Allergy. 1947;18:199–211.

22. Hackett TL. Epithelial-mesenchymal transition in the pathophysiology of airway remodelling in asthma. Curr Opin Allergy Clin Immunol. 2012;12:253–9.

23. Hackett TL, Warner SM, Stefanowicz D, Shaheen F, Pechkovsky DV, Murray LA, Argenteri R, Kicic A, Stankovic SM, Bai TR, Knight DA. Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-beta1. Am J Respir Crit Care Med. 2009;180:222–33.

24. Johnson JR, Nishioka M, Chakir J, Rissee PA, Almaghlouth I, Bazzebashi AN, Plante S, Martin JG, Eidelman D, Hamid Q, IL-22 contributes to TGF-beta1-mediated epithelial-mesenchymal transition in asthmatic bronchial epithelial cells. Respir Res. 2013;14:118.

25. Pain M, Bermudez O, Lacoste P, Royer PJ, Botturi K, Tissot A, Brouard S, Eickelberg O, Magnan A. Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype. Eur Respir Rev. 2014;23:118–30.

26. Yang ZC, Yi MJ, Pan N, Wang C, Fu P, Feng XY, Xu L, Qu ZH. Transforming growth factor-beta1 induces bronchial epithelial cells to mesenchymal transition by activating the Snail pathway and promotes airway remodeling in asthma. Mol Med Rep. 2013;8:1663–8.

27. Gauldie J, Bonnassaud P, Sme P, Ask K, Kolb M. TGF-beta, Smad3 and the process of progressive fibrosis. Biochem Soc Trans. 2007;35:661–4.

28. Hansel TT, Braunstein JB, Walker C, Blaser K, Brujinzeel PL, Virchow J, Virchow Sr C. Sputum eosinophils from asthmatics express ICAM-1 and HLA-DR. Clin Exp Immunol. 1991;86:271–7.

29. Laudanna C, Campbell JJ, Butcher EC. Elevation of intracellular cAMP inhibits RhoA activation and integrin-dependent leukocyte adhesion induced by chemoattractants. J Biol Chem. 1997;272:24141–4.

30. Hu P, Shen M, Zhang P, Zheng C, Pang Z, Zhu L, Du J. Infiltrating neutrophil granulocytes contribute to epithelial-mesenchymal transition in lung adenocarcinoma cells. Tumour Biol. 2015;36:7789–96.

31. Yang Z, Xie H, He D, Li L. Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling. Oncotarget. 2016;7:44478–91.

32. Grange CL, Lau LCK, Ward JA, Duly Y, Lahiff G, Wilson S, Holgate S, Davies DE, Howarth PH. Effect of bronchocoonstriction on airway remodeling in asthma. N Engl J Med. 2011;364:2006–15.